Amarin Corp PLC (AMRN)
0.7052
+0.02
(+2.80%)
USD |
NASDAQ |
Jul 02, 16:00
0.7052
0.00 (0.00%)
After-Hours: 18:03
Amarin Research and Development Expense (Annual): 22.22M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 22.22M |
| December 31, 2022 | 30.41M |
| December 31, 2021 | 29.31M |
| December 31, 2020 | 38.96M |
| December 31, 2019 | 34.39M |
| December 31, 2018 | 55.90M |
| December 31, 2017 | 47.16M |
| December 31, 2016 | 49.98M |
| December 31, 2015 | 51.06M |
| December 31, 2014 | 50.33M |
| December 31, 2013 | 72.75M |
| December 31, 2012 | 58.96M |
| December 31, 2011 | 21.60M |
| December 31, 2010 | 28.01M |
| Date | Value |
|---|---|
| December 31, 2009 | 20.89M |
| December 31, 2008 | 12.95M |
| December 31, 2007 | 12.11M |
| December 31, 2006 | 17.19M |
| December 31, 2005 | 8.92M |
| December 31, 2004 | 1.205M |
| December 31, 2003 | 5.442M |
| December 31, 2002 | 6.219M |
| December 31, 2001 | 4.137M |
| December 31, 2000 | 5.034M |
| December 31, 1999 | 6.331M |
| August 31, 1999 | |
| August 31, 1998 | 8.60M |
| August 31, 1997 | 19.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
22.22M
Minimum
2023
38.96M
Maximum
2020
31.06M
Average
30.41M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Trinity Biotech PLC | 4.379M |
| Cellectis SA | 87.65M |
| Adaptimmune Therapeutics PLC | 126.51M |
| Akari Therapeutics PLC | 5.45M |
| Biodexa Pharmaceuticals Plc | -- |